{'output': [['Seattle Genetics Inc', 'COMP', 'Announce', 'FDA grants priority review status', 'EVENT'], ['Seattle Genetics Inc', 'COMP', 'Produce', 'ADCETRIS®', 'PRODUCT'], ['ADCETRIS®', 'PRODUCT', 'Control', 'Hodgkin Lymphoma treatment', 'PRODUCT'], ['FDA grants priority review status', 'EVENT', 'Relate_To', 'Supplemental Biologics License Application', 'EVENT'], ['Supplemental Biologics License Application', 'EVENT', 'Operate_In', 'FDA', 'ORG/GOV'], ['ADCETRIS®', 'PRODUCT', 'Impact', 'Frontline Advanced Hodgkin Lymphoma', 'CONCEPT'], ['Prescription Drug User Fee Act', 'EVENT', 'Has', 'May 1, 2018', 'DATE']]}